Prophylactic and nutraceutical therapy
A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.
1. A composition comprising:
(a) an extract of milk comprising α-lactalbumin, wherein the extract of milk was defatted and subjected to a reduction in protein concentration;
(b) at least a 70 times molar excess of oleic acid or salt thereof; and
(c) an acidifying agent that reduces the pH of the composition to about 2;
wherein the composition has been heat-treated, and the composition comprises a biologically active complex of α-lactalbumin and oleic acid or salt thereof.
2. The composition of claim 1 wherein component (b) is an oleate salt.
3. The composition of claim 1 wherein component (a) is human or bovine.
4. The composition of claim 1 wherein component (c) is an inorganic acid.
5. The composition of claim 1 which is a nutraceutical.
6. A method for preparing the composition of claim 1 , said method comprising:
forming a mixture comprising the extract of milk and the oleic acid or salt thereof, wherein the oleic acid or salt thereof is present in 70-100 times molar excess;
lowering the pH of the mixture to about 2 with the acidifying agent; and
heating the mixture to about 50° C. for about 20-60 minutes.
7. A method for preventing or treating a proliferative disease, said method comprising administering to an individual in need thereof an effective amount of the composition of claim 1 , wherein the proliferative disease is colon cancer.
8. The method of claim 7 wherein the composition is administered orally.